New Insights into Current and Future Vaccines against SARS-CoV-2 Variants of Concern and Interest
Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 15570
2. European Virus Bioinformatics Center (EVBC), Jena, Germany
Interests: coronavirus; SARS-CoV-2; variant of concern; vaccine evaluation; T Lymphocytes; HBV
Special Issues, Collections and Topics in MDPI journals
The coronavirus disease 2019 (COVID-19) pandemic has been a worldwide threat in the last two years, leading to more than 239 million confirmed infection cases and 4.8 million deaths. So far, no curative medications specific for the pathogen SARS-CoV-2 are available. Despite the availability of prophylactic vaccines, it remains a major public health problem due to at least two facts: (1) low numbers of vaccine doses in developing countries and (2) variants generated during its robust replication and rapid spreading in unvaccinated individuals.
As of 31st May 2021, the World Health Organization (WHO) proposed SARS-CoV-2 variants of concern (VOC), of interest (VOI) and of high consequence/under monitoring. However, all WHO-approved vaccines, i.e., Comirnaty, Spikevax, Vaxzevria, Janssen COVID-19 vaccine, BBIBP-CorV and CoronaVac were manufactured relying on the original virus. Nowadays, breakthrough infections occur in vaccinated people, although they experience alleviated severity and lower mortality.
We are pleased to invite you to contribute to the Special Issue entitled “New Insights into Current and Future Vaccines Against Sars-Cov-2 Variants of Concern and Interest”. This issue will provide an overview of humoral and cellular immunity induced by current SARS-CoV-2 vaccines, with topics especially regarding, but not limited to, two scientific issues: (1) strategies to elongate humoral and cellular immune responses induced by vaccine(s), and (2) development of future vaccines for VOC and VOI. Research articles, communications and reviews are welcome.
We look forward to receiving your contributions.
Dr. Bingqian Qu
Dr. Xue Li
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- variants of concern
- variants of interest
- neutralizing antibody
- antigenic shift
- immune escape
- cellular immunity
- multivalent vaccine
- variant-modified mRNA
- vaccine evaluation